A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with ..

Printer-friendly versionSend by emailPDF version

Name

ImmunoGen Incorporated

Anticipated Amount

446 137.00

Activity Type

Clinical Trial

Award Type

Contract

Date

December 6, 2011 to December 8, 2014

Award Number

005262-00001

Sponsor Award Number

IMGN901

Award Contacts

Name

Garland,Linda L

Title

Principal Investigator

Unit

Cancer Center Division

UA@Work is produced by University Communications

888 N. Euclid Ave., Ste. 413 (or) 
P.O. Box 210158, Tucson, AZ 85721

T 520.621.1877  F 520.626.4121

Feedback

2018 © The Arizona Board of Regents on behalf of the University of Arizona